Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

Uncontrolled proliferative signals and cell cycle dysregulation due to genomic or functional
alterations are important drivers of the expansion of undifferentiated blast cells in acute …

FLT3 inhibitors as single agents have limited effects because of acquired and adaptive
resistance and the cardiotoxicity related to human ether-a-go-go-related gene (hERG) …

Herein, we report two promising compounds 30 and 36 possessing nanomolar FLT3
inhibitory activities (IC50= 1.5–7.2 nM), high selectivity over c-KIT (> 1000-fold), and …

Aurora Kinase B is a serine-threonine kinase known to be overexpressed in several
cancers, with no inhibitors approved for clinical use. Herein, we present the discovery and …

Gene fusions and point mutations of RET kinase are crucial for driving thoracic cancers,
including thyroid cancer and non-small cell lung cancer. Various scaffolds based on different …

Overexpression and frequent mutations in FMS-like tyrosine kinase-3 (FLT3) are considered
risk factors for severe acute myeloid leukemia (AML). Hyperactive FLT3 induces premature …

FMS-like tyrosine kinase 3 (FLT3) with an internal tandem duplication (ITD) mutation has
been validated as a driver lesion and a therapeutic target for acute myeloid leukemia (AML) …

Mutations of the rearranged during transfection (RET) kinase are frequently reported in
cancer, which make it as an attractive therapeutic target. Herein, we discovered a series of N …

Secondary pharmacology screening of investigational small-molecule drugs for potentially
adverse off-target activities has become standard practice in pharmaceutical research and …